

Panel on Dietetic products, Nutrition and Allergies

29 June 2012

**MINUTES OF THE 47TH PLENARY MEETING OF THE
SCIENTIFIC PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES
HELD FROM 26 TO 29 JUNE 2012**

PARTICIPANTS

Panel members:

- Carlo Agostoni
- Susan Fairweather Tait
- Albert Flynn
- Ines Golly
- Hannu Korhonen
- Martinus Løvik
- Ambroise Martin
- Bevan Moseley
- Monika Neuhäuser-Berthold
- Hildegard Przyrembel
- Seppo Salminen ²
- Yolanda Sanz ¹
- Sean Strain
- Stephan Strobel
- Inge Tetens ³
- Daniel Tomé
- Hendrik van Loveren ¹
- Hans Verhagen

¹ Present on 27, 28 and 29 June 2012 only

² Present on 26, 27 and 28 June 2012 only

³ Present on 27 and 28 June 2012 only

⁴ Present on 26 and 27 June 2012 only

EFSA staff:

- Juliane Kleiner
- Reinhard Ackerl
- Maria Astridou
- Anja Bronstrup
- Janusz Ciok
- Céline Dumas
- Wolfgang Gelbmann
- Leng Heng
- Danai Papanastasiou
- Ariane Titz
- Emanuela Turla
- Silvia Valtueña Martínez

European Commission:

- Sabine Osaer ⁴ (European Commission)
- Christina Antoniou ¹ (European Commission)

1. WELCOME, APOLOGIES FOR ABSENCE

The Chair welcomed all participants to the plenary meeting. Apologies were received from Jean-Louis Bresson, Pagona Lagiou and Rosangela Marchelli.

2. ADOPTION OF THE AGENDA AND THE MINUTES OF LAST PLENARY

The agenda of the meeting and the minutes of the 46th Plenary meeting were adopted.

3. DECLARATIONS OF INTEREST

EFSA Secretariat screened the Annual Declaration of interest (ADoI) and Specific Declaration of interest (SDoI) filled in by the scientific experts invited to this meeting in accordance with EFSA's Policy on Declarations of Interests.

In relation to the application from *DSM on Zeaxanthin* (item 10.3), Sean Strain declared an interest and refrained from the discussion for this agenda item.

Hans Verhagen declared an interest before the meeting related to the application from *Health Concern* on "plant sterols and Cholesternorm mix" and "reduction of cholesterol concentrations" (item 8.12) and refrained from the discussion for this agenda item.

With regard to the other items on the agenda for this meeting, no conflicts of interests were identified at the beginning of this meeting.

4. FEEDBACK FROM EFSA SCIENTIFIC COMMITTEE AND OTHER EFSA PANELS, GENERAL INFORMATION FROM EFSA

In relation to the activities related to the EFSA Scientific Committee, members were informed that the opinion on Threshold of Toxicological Concern was adopted at the last scientific committee Plenary meeting.

Panel members were also informed that EFSA had published the names of new members of the EFSA's Scientific Committee and eight of its Panels. These members will serve from 1 July 2012 onwards for a three year term (<http://www.efsa.europa.eu/en/press/news/120618.htm>).

EFSA will be holding an International scientific conference on health claims next year. The exact date, venue and programme will be communicated at a later stage.

Members were informed that in line with its commitment to openness and transparency, EFSA management has suggested that at least one open Plenary meeting should be organised for each of the 10 Scientific Panels and the Scientific Committee in 2012/2013.

5. FEEDBACK FROM THE EUROPEAN COMMISSION ON MATTERS RELATING TO THE PANEL

The Commission provided an updated feedback on the status and of its decision-making relating to the EFSA adopted scientific opinions and the Art 13(1) health claims that were placed on hold.

The Commission representatives also took this opportunity to express their thanks and appreciation to the NDA Panel and the EFSA Secretariat for the tremendous scientific works delivered within tight deadlines and for the excellent cooperation between EFSA Secretariat, the NDA Panel and the Commission Services.

6. NEW REQUESTS

Two new requests were received from the European Commission requesting EFSA to carry out additional assessment related to the safety: of “**Rooster Comb extract**”, and of “**Methyl Vinyl Ether-Maleic Anhydride Copolymer Gantrez® (novel chewing gum base)**”, submitted in accordance with the Novel Foods Regulation 258/97/EC, as novel food ingredient.

One new request was received from the European Commission asking EFSA to review and update its existing opinion related to “**Cetyl Myristoleate Complex (Myrisana)** as novel food ingredients” in the light of the additional information available.

7. GENERAL ISSUES ON HEALTH CLAIMS EVALUATIONS

7.1 Update on Article 13(5) and 14 applications

The Secretariat informed the Panel about the status of claims applications since the last Plenary meeting.

Article 13(5) claims (claims based on newly developed science and/or which include a request for the protection of proprietary data): Since the last meeting, eleven new applications pursuant to 13(5) claims were received: Femilub and vaginal dryness; Grape seed extract and water accumulation; OXY280 and weight loss; Cynatine and joint flexibility; Lactibiane Reference and intestinal comfort; Lactibiane Reference and intestinal transit, green tea including EGCG and guarana and fat burn; EFAX TM and menstruation cycle; Lycopene, vitamin E, lutein and selenium and sensitive skin; Lycopene, vitamin E, lutein and selenium and skin tanning; Silicon dioxide and nails, hair and connective tissue. One application on “Flaxseed oil and vitamin E and skin irritation” (from Nutrilinks) was withdrawn further to a request from the Competent Authority of Belgium. One application on “Glucose (synonymous dextrose) and refilling of glycogen stores” (from Dextro Energy GmbH & Co. KG) was withdrawn further to a request from the Competent Authority of Germany.

Article 14 claims: Since the last meeting, one new disease risk reduction claim application was received: EPA and AA/EPA fatty acid ratio in blood. One disease risk reduction claim application on “Apple cultivar “Santana” and allergic responses” (from Applied Plant Research/Wageningen) was withdrawn further to a request from the Competent Authority of the Netherlands. One children’s claim application on “*Lactobacillus rhamnosus* GG (LGG) in Yoplait EveryKid fermented dairy milk and strengthen immunity” (from Glanbia Consumer Foods) was withdrawn further to a request from the Competent Authority of Ireland.

Rapporteurs have been appointed for the new applications received.

7.2 Draft guidance on the scientific requirements for health claims related to neurological and psychological functions (EFSA-Q-2010-01185)

Following the online public consultation of the above-mentioned draft guidance document, a revised draft guidance document, which took into consideration relevant comments received, was discussed and adopted on 28 June by the Panel subject to the incorporation of editorial changes. The NDA Panel members expressed their gratitude for the many useful comments received, and which helped to improve the document. Due to the specific technical nature of many of the comments received, the Panel felt that these comments could be best addressed in written form via the technical report (see 7.3).

The final text of the guidance document is published together with a Summary Report of the comments received during the online-consultation phase (see 7.3) via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/2816.htm>.

7.3 **Technical report: Outcome of a public consultation on the Draft guidance on the scientific requirements for health claims related to neurological and psychological functions (EFSA-Q-2011-01097)**

A technical report on the Outcome of a public consultation of a draft guidance on the scientific requirements for health claims related to neurological and psychological functions summarised the comments received during the public consultation of this guidance (opened from 17 October 2011 until 16 December 2011). This report was presented, discussed and subsequently endorsed by the Panel on 28 June.

The technical report is published together with the guidance document via the following link: <http://www.efsa.europa.eu/en/supporting/pub/314e.htm>.

7.4 **Draft guidance on the scientific requirements for health claims related to physical performance (EFSA-Q-2010-01186)**

Following the online public consultation of the above-mentioned draft guidance document, a revised draft guidance document, which took into consideration relevant comments received, was discussed and adopted on 28 June by the Panel subject to the incorporation of editorial changes. The NDA Panel members expressed their gratitude to those who provided comments, which helped to improve the document. Due to the specific technical nature of the comments received, the Panel felt that these comments could be best addressed in written form via the technical report (see 7.5).

The final text of the guidance document is published together with a Summary Report of the comments received during the online-consultation phase (see 7.5) via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/2817.htm>.

7.5 **Technical report: Outcome of a public consultation on the Draft guidance on the scientific requirements for health claims related to physical performance (EFSA-Q-2011-01269)**

A technical report on the Outcome of a public consultation of a draft guidance on the scientific requirements for health claims related to physical performance, which summarises the comments received during the public consultation of this guidance (opened from 19 December 2011 until 9 March 2012) was presented, discussed and subsequently endorsed by the Panel on 28 June.

The technical report is published together with the guidance document via the following link: <http://www.efsa.europa.eu/en/supporting/pub/315e.htm>.

8. **APPLICATIONS PURSUANT TO ARTICLES 14/13(5) OF REGULATION (EC) NO 1924/2006**

8.1 *Lesaffre International* - “*Saccharomyces cerevisiae* var. *boulardii* CNCM I-3799” and “intestinal comfort” (Art. 13(5); 0327_FR; EFSA-Q-2012-00271)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2801.htm>.

8.2 *Nutrilinks* - “OptiEFAX™” and “maintenance of normal blood LDL-cholesterol concentrations” (Art. 13.5; 0334_BE; EFSA-Q-2012-00339)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/scdocs/scdoc/2802.htm>.

8.3 Nutrilinks - “OptiEFAX™” and “maintainance of normal blood HDL-cholesterol concentrations” (Art. 13.5; 0335_BE; EFSA-Q-2012-00340)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2803.htm>.

8.4 Nutrilinks - “OptiEFAX™” and “maintenance of normal blood concentrations of triglycerides” (Art. 13.5; 0338_BE; EFSA-Q-2012-00383)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2804.htm>.

8.5 Nutrilinks – “Hyaluronic acid” and “helps to maintain good skin hydration” (Art. 13.5, 0337_BE, EFSA-Q-2012-00382)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2806.htm>.

8.6 Nutrilinks – “Rhodiola rosae” and “helps to reduce tiredness in case of stress” (Art. 13.5; 0331_BE; EFSA-Q-2012-00336)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2805.htm>.

8.7 Nutrilinks – “Group B vitamins and pumpkin seed oil” and “maintenance of normal hair” (Art. 13.5; 0329_BE and 0330_BE; EFSA-Q-2012-00334 and EFSA-Q-2012-00335)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2807.htm>.

8.8 Nutrilinks – “Keratin, copper, zinc, group B vitamins” and “maintenance of normal hair” (Art. 13.5; 0336_BE; EFSA-Q-2012-00381)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2808.htm>.

8.9 Barry Callebaut Belgium NV-“Cocoa flavonols” and “endothelium-dependent vasodilation” (Art. 13(5); 0319_BE; EFSA-Q-2012-00002)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2809.htm>.

8.10 Extraction Purification Innovation France - “Wheat polar lipid extract” and “protection of the skin against dehydration” (Art. 13(5); 0315_FR; EFSA-Q-2011-01122)

The draft opinion was adopted by the Panel by written procedure on 22 June 2012. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2773.htm>.

8.11 Nutrilinks – “Flaxseed oil and vitamin E” and “contributes to maintain skin permeability barrier function” (Art. 13.5; 0332_BE; EFSA-Q-2012-00337)

The discussion of this agenda item was postponed to the next Panel plenary meeting.

8.12 Health Concern - “plant sterols and Cholesternorm mix” and “reduction of cholesterol concentrations” (Art. 14: 0314_NL and 0239_NL; EFSA-Q-2011-01114 and EFSA-Q-2009-00237)

On 27 June, the draft opinion was discussed and **adopted** by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2810.htm>.

8.13 Vivatech - “Transitech®” and “reduction of transit time” (Art. 13.5, 0328_FR, EFSA-Q-2012-00293)

On 28 June, the draft opinion was presented and discussed. The Panel identified a number of issues for which additional information is needed from the applicant before the Opinion can be concluded. The stop the clock procedure will be applied.

9. FURTHER ASSESSMENT OF ARTICLE 13 CLAIMS

9.1. Soy isoflavones & vasomotor symptoms associated with menopause (ID 1654-EFSA-Q-2012-00165; 1704-EFSA-Q-2012-00167; 2140-EFSA-Q-2012-00170; 3093-EFSA-Q-2012-00212; 3154-EFSA-Q-2012-00213; 3590-EFSA-Q-2012-00214) & bone mineral density (ID 1655-EFSA-Q-2012-00166)

On 27 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2847.htm>

9.2. Polyphenols in olive & HDL cholesterol concentrations (ID 1639-EFSA-Q-2012-00164)

The draft opinion was discussed on 27 June and adopted on 28 June by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2848.htm>

9.3. A combination of “*L. helveticus* CNCM I-1722 and *B. longum* subsp. *Longum* CNCM I-3470” and alleviation of stress-induced symptoms (ID 938) (EFSA-Q-2012-00130)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes (see also 9.6: this opinion has been clustered together with 9.6). The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2849.htm>

9.4. “*L. paracasei* LPC 01 (CNCM I-1390)” and treatment of disease (ID 3055) (EFSA-Q-2012-00208)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2850.htm>

9.5. “*B. lactis* BS 01 (LMG P-21384)” and improvement of bowel function and reduction of abdominal bloating (ID 2940) (EFSA-Q-2012-00176)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2851.htm>

9.6. *Lactobacillus helveticus* CNCM I-1722 and *Bifidobacterium longum* subsp. *longum* CNCM I-3470 and “maintains the balance of healthy microbiota that helps to strengthen the natural defence” (ID 2942) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 (EFSA-Q-2012-00178)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes (see also 9.3). The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2849.htm>

9.7. “*L. helveticus* CNCM I-1722, *B. infantis* CNCM I-3424, *B. bifidum* CNCM I-3426 and FOS from sucrose” and defence against pathogens (ID 3016) (EFSA-Q-2012-00204)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2852.htm>

9.8. A combination of *Lactobacillus rhamnosus* CNCM I-1720, *Lactobacillus helveticus* CNCM I-1722, *Bifidobacterium longum* CNCM I-3470 and *Saccharomyces boulardii* CNCM I-1079 and defence against pathogenic gastro-intestinal microorganisms (ID 3017) (EFSA-Q-2012-00205)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2853.htm>

9.9. “*B. breve* BR 03 (DSM 16604)” and “intestinal mobility” (ID 2936) (EFSA-Q-2012-00173)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.10. “*B. longum* BL 03 (DSM 16603)” and “intestinal mobility” (ID 2937) (EFSA-Q-2012-00174)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.11. “*B. breve* BR03 (DSM 16604) and *L. plantarum* LP01 (LMG P-21021)” and “reducing gastrointestinal discomfort associated with increased transit time” (ID 2938) (EFSA-Q-2012-00175)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.12. A combination of *Bifidobacterium lactis* BS01, *Lactobacillus rhamnosus* LR04 and *Lactobacillus plantarum* LP02 and short-chain fructo-oligosaccharides “defence against upper respiratory tract infections” (ID 2941) (EFSA-Q-2012-00177)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.13. A combination of *Lactobacillus acidophilus* LA02 and *Lactobacillus plantarum* LP01 (ID 2944) and “relieve of abdominal discomfort and pain” (ID 2944) (EFSA-Q-2012-00179)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.14. “*L. plantarum* LP 01 (LMG P-21021)” and “intestinal mobility” (ID 2965) (EFSA-Q-2012-00193)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.15. *Lactobacillus rhamnosus* LR04 and “balancing intestinal flora, improves skin, scalp and hair health” (ID 2968) and “reduce the daily number of bowel movements” (ID 2969) (EFSA-Q-2012-00196, EFSA-Q-2012-00197)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.16. “*B. adolescentis* BA 02 (DSM 17103)” and “intestinal motility” (ID 3035) (EFSA-Q-2012-00206)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.17. A combination of *Bifidobacterium lactis* BS01, *Lactobacillus rhamnosus* LR04, *Lactobacillus rhamnosus* LR05, *Lactobacillus plantarum* LP01 and *Lactobacillus plantarum* LP02 and short-chain fructo-oligosaccharides or galacto-oligosaccharides and “defence against upper respiratory tract infections” (ID 3047) (EFSA-Q-2012-00207)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

9.18. “*B. longum* W11 (LMG P-21586)” and “relieve of abdominal discomfort and bloating” (ID 3056) (EFSA-Q-2012-00209)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

- 9.19. A combination of *Bifidobacterium lactis* BS01, *Lactobacillus rhamnosus* LR04, *Lactobacillus plantarum* LP02, lactoferrin and short-chain fructo-oligosaccharides (ID 3059) and “defence against upper respiratory tract infections” (EFSA-Q-2012-00210)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2854.htm>

- 9.20. A combination of *L. paracasei* CNCM I 1688 and *L. salivarius* CNCM I 1794 and reduction of GI discomfort (ID 2972), decreasing potentially pathogenic GI microorganisms (ID 2972), improved lactose digestion (ID 2972) and increasing IL-10 production (ID 2973) (EFSA-Q-2012-00200, EFSA-Q-2012-00201)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2856.htm>

- 9.21. A combination of *L. acidophilus* BCCM/LMG P 18806, *L. delbrueckii* BCCM/LMG P 18805 and *S. thermophilus* BCCM/LMG P 18807, and reduction of GI discomfort (ID 2946, 2951, 2974), decreasing potentially pathogenic GI microorganisms (ID 2946, 2951, 2974), improved lactose digestion (ID 2946, 2951, 2974) and reduction in numbers of circulating CD34+ cells (ID 2947, 2952, 2975) (EFSA-Q-2012-00180, EFSA-Q-2012-00181, EFSA-Q-2012-00184, EFSA-Q-2012-00185, EFSA-Q-2012-00202, EFSA-Q-2012-00203)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2855.htm>

- 9.22. “*B. animalis* ssp *lactis* THT 010801” and changes in bowel function and digestion and absorption of nutrients (ID 960, 961), decreasing potentially pathogenic GI microorganisms (ID 960), and stimulation of immunological responses (ID 962) (EFSA-Q-2012-00133, EFSA-Q-2012-00134, EFSA-Q-2012-00135)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.23. “*B. longum* ssp *infantis* THT 010201” and changes in bowel function and digestion and absorption of nutrients (ID 967), decreasing potentially pathogenic GI microorganisms (ID 967), and stimulation of immunological responses (ID 968) (EFSA-Q-2012-00136, EFSA-Q-2012-00137)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.24. “*B. longum* ssp *longum* THT 010301” changes in bowel function and digestion and absorption of nutrients (ID 969), decreasing potentially pathogenic GI microorganisms (ID 969), and stimulation of immunological responses (ID 970) (EFSA-Q-2012-00138, EFSA-Q-2012-00139)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.25. ***B. pseudolongum* ssp *pseudolongum* THT 010501** and changes in bowel function and digestion and absorption of nutrients (ID 971), decreasing potentially pathogenic GI microorganisms (ID 971), and stimulation of immunological responses (ID 972) (EFSA-Q-2012-00140, EFSA-Q-2012-00141)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.26. ***L. casei* THT 030401** and changes in bowel function and digestion and absorption of nutrients (ID 975), decreasing potentially pathogenic GI microorganisms (ID 975), and stimulation of immunological responses (ID 976) (EFSA-Q-2012-00143, EFSA-Q-2012-00142)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.27. ***L. gasseri* THT 031301** and changes in bowel function and digestion and absorption of nutrients (ID 983), decreasing potentially pathogenic GI microorganisms (ID 983), and stimulation of immunological responses (ID 984) (EFSA-Q-2012-00144, EFSA-Q-2012-00145)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.28. ***L. helveticus* THT 031102** and changes in bowel function and digestion and absorption of nutrients (ID 985), decreasing potentially pathogenic GI microorganisms (ID 985), and stimulation of immunological responses (ID 986) (EFSA-Q-2012-00146, EFSA-Q-2012-00147)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.29. ***L. plantarum* THT 030701** and changes in bowel function and digestion and absorption of nutrients (ID 994), decreasing potentially pathogenic GI microorganisms (ID 994), and stimulation of immunological responses (ID 995) (EFSA-Q-2012-00148, EFSA-Q-2012-00149)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.30. ***L. plantarum* THT 030707** and changes in bowel function and digestion and absorption of nutrients (ID 996), decreasing potentially pathogenic GI microorganisms (ID 996), and stimulation of immunological responses (ID 997) (EFSA-Q-2012-00150, EFSA-Q-2012-00151)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

- 9.31. ***L. reuteri* THT 030802** and changes in bowel function and digestion and absorption of nutrients (ID 998), decreasing potentially pathogenic GI microorganisms (ID 998), and

stimulation of immunological responses (ID 999) (EFSA-Q-2012-00152, EFSA-Q-2012-00153)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

9.32. “*L. salivarius* THT 031001” and changes in bowel function and digestion and absorption of nutrients (ID 1006), decreasing potentially pathogenic GI microorganisms (ID 1006), and stimulation of immunological responses (ID 1007) (EFSA-Q-2012-00154, EFSA-Q-2012-00155)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

9.33. “*S. thermophilus* THT 070102” and changes in bowel function and digestion and absorption of nutrients (ID 1014), decreasing potentially pathogenic GI microorganisms (ID 1014) and stimulation of immunological responses (ID 1015) (EFSA-Q-2012-00158, EFSA-Q-2012-00159)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2857.htm>

9.34. “*L. crispatus* BCCM/LMG P 17631” and reduction of GI discomfort (ID 1030), decreasing potentially pathogenic GI microorganisms (ID 1030), improved lactose digestion (ID 1030) and defence against vaginal pathogens (ID 2950) (EFSA-Q-2012-00160, EFSA-Q-2012-00183)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

9.35. “*L. gasseri* BCCM/LMG P 17632” and reduction of GI discomfort (ID 2956), decreasing potentially pathogenic GI microorganisms (ID 2956) and improved lactose digestion (ID 2956) (EFSA-Q-2012-00186)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

9.36. “*L. gasseri* BCCM/LMG P 18137” and defence against vaginal pathogens (ID 2957), reduction of GI discomfort (ID 2958), decreasing potentially pathogenic GI microorganisms (ID 2958) and improved lactose digestion (ID 2958) (EFSA-Q-2012-00187, EFSA-Q-2012-00188)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

9.37. “*L. paracasei* CNCM I 1687” and increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2960), reduction of GI discomfort (ID 2961), decreasing potentially pathogenic GI microorganisms (ID 2961) and improved lactose digestion (ID 2961) (EFSA-Q-2012-00189, EFSA-Q-2012-00190)

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

- 9.38. “*L. paracasei* CNCM I 1688” and increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2962), reduction of GI discomfort (ID 2963), decreasing potentially pathogenic GI microorganisms (ID 2963) and improved lactose digestion (ID 2963) (EFSA-Q-2012-00191, EFSA-Q-2012-00192)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

- 9.39. “*L. plantarum* BCCM/LMG P 17630” and reduction of GI discomfort (ID 2966), decreasing potentially pathogenic GI microorganisms (ID 2966), improved lactose digestion (ID 2966) and defence against vaginal pathogens (ID 2967) (EFSA-Q-2012-00194, EFSA-Q-2012-00195)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

- 9.40. “*L. salivarius* CNCM I 1794” and reduction of GI discomfort (ID 2970), decreasing potentially pathogenic GI microorganisms (ID 2970), improved lactose digestion (ID 2970) and increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2971) (EFSA-Q-2012-00198, EFSA-Q-2012-00199)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

- 9.41. A combination of “*B. animalis* ssp. *lactis* Bf-6/Bif-6/CB111 and *L. johnsonii* La-1/ACD-1/CLbA22 (A/B-61)” and “intestinal flora/digestive health” (ID 4231) (EFSA-Q-2012-00215)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2858.htm>

10. NOVEL FOODS

- 10.1. Morinaga Milk Industry Co Ltd - Bovine Lactoferrin (EFSA-Q-2011-00974)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2811.htm>.

- 10.2. Ajinomoto – Dihydrocapsiate (EFSA-Q-2011-01155)**

On 28 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2812.htm>

- 10.3. DSM – Zeaxanthin (EFSA-Q-2012-00418)**

On 29 June, the draft opinion was presented and discussed. A revised draft opinion will be discussed at the next Standing working group on novel foods meeting.

11. DIETARY REFERENCE VALUES

11.1. Energy (EFSA-Q-2008-465)

On 28 June, the draft opinion was discussed and endorsed for release for public consultation.

12. TOLERABLE UPPER INTAKE LEVEL

12.1. Calcium (EFSA-Q-2011-00956)

On 26 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2814.htm>

12.2. Vitamin D (EFSA-Q-2011-00955)

On 26 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2813.htm>

12.3. Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) (EFSA-Q-2011-00834)

On 26 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2815.htm>

13. ANY OTHER BUSINESS

The chair closed the last NDA Plenary in this mandate (2009-2012) expressing his great appreciation to all members of NDA Panel and the NDA secretariat for their hard work, collegiality and high commitment. The Secretariat took the opportunity to express also on behalf of EFSA its sincere gratitude to the Panel and its members for their excellent contribution, their continuous support and high commitment to the work of the Panel. The Secretariat also expressed EFSA acknowledgement to the Panel's Chair, Albert Flynn, for his outstanding scientific judgement and for leading the NDA Panel during the last nine years.

The minutes of the 47th Plenary meeting were agreed by written procedure on 29 July 2012.